📊 BVS Key Takeaways
Is Bioventus Inc. (BVS) a Good Investment?
Bioventus demonstrates concerning fundamental deterioration with revenue declining and net income falling 16.7% YoY, while generating inadequate returns on equity (1.6%) and assets (0.5%). Despite strong gross margins of 68.7%, razor-thin operating (6.4%) and net margins (2.4%) combined with high leverage (1.34x D/E) and significant debt burden ($253.3M) relative to cash position ($35.8M) suggest mounting operational and financial pressure.
Bioventus shows a fundamentally mixed profile: solid gross margins, positive operating leverage, and strong free cash flow generation support the business, but revenue is slightly declining and net income remains relatively thin versus sales. Financial health is adequate with acceptable liquidity, yet leverage is still meaningful, so the company looks operationally stable rather than clearly high-quality or high-growth.
Why Buy Bioventus Inc. Stock? BVS Key Strengths
- Strong gross margin of 68.7% indicates product pricing power and cost management
- Adequate liquidity position with current ratio of 1.69x and positive free cash flow of $8.4M
- Operating in medical device sector with structural growth tailwinds and high barriers to entry
- High gross margin of 68.3% indicates strong product economics and pricing power
- Free cash flow of $72.11M and a 12.7% FCF margin show good cash conversion
- Positive operating income and double-digit ROE suggest the business is profitable on a normalized basis
BVS Stock Risks: Bioventus Inc. Investment Risks
- Declining revenue (-0.9% YoY) and sharply falling net income (-16.7% YoY) signal business contraction
- Extremely poor returns on equity (1.6%) and assets (0.5%) indicate inefficient capital deployment
- High financial leverage (1.34x D/E ratio) with $253.3M long-term debt against only $35.8M cash creates debt service vulnerability
- Revenue declined 0.9% year over year, pointing to weak top-line momentum
- Net margin of 4.0% is modest, leaving limited room for execution missteps or cost pressure
- Debt-to-equity of 1.52x and long-term debt of $278.95M keep leverage risk elevated
Key Metrics to Watch
- Revenue growth trajectory and whether declines stabilize or accelerate
- Operating margin expansion potential given strong gross margins
- Debt reduction progress and cash flow adequacy to service debt obligations
- Revenue growth and operating margin trend
- Free cash flow generation relative to debt reduction
Bioventus Inc. (BVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Bioventus Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BVS Profit Margin, ROE & Profitability Analysis
BVS vs Healthcare Sector: How Bioventus Inc. Compares
How Bioventus Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioventus Inc. Stock Overvalued? BVS Valuation Analysis 2026
Based on fundamental analysis, Bioventus Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioventus Inc. Balance Sheet: BVS Debt, Cash & Liquidity
BVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioventus Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.49 indicates the company is currently unprofitable.
BVS Revenue Growth, EPS Growth & YoY Performance
BVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $123.9M | -$2.6M | $-0.04 |
| Q3 2025 | $138.7M | $3.2M | $0.05 |
| Q2 2025 | $147.7M | $4.8M | $0.07 |
| Q1 2025 | $123.9M | -$2.6M | $-0.04 |
| Q3 2024 | $120.8M | -$4.8M | $-0.07 |
| Q2 2024 | $137.1M | -$3.7M | $-0.06 |
| Q1 2024 | $119.1M | -$4.6M | $-0.07 |
| Q3 2023 | $120.8M | -$7.3M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioventus Inc. Dividends, Buybacks & Capital Allocation
BVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioventus Inc. (CIK: 0001665988)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BVS
What is the AI rating for BVS?
Bioventus Inc. (BVS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BVS's key strengths?
Claude: Strong gross margin of 68.7% indicates product pricing power and cost management. Adequate liquidity position with current ratio of 1.69x and positive free cash flow of $8.4M. ChatGPT: High gross margin of 68.3% indicates strong product economics and pricing power. Free cash flow of $72.11M and a 12.7% FCF margin show good cash conversion.
What are the risks of investing in BVS?
Claude: Declining revenue (-0.9% YoY) and sharply falling net income (-16.7% YoY) signal business contraction. Extremely poor returns on equity (1.6%) and assets (0.5%) indicate inefficient capital deployment. ChatGPT: Revenue declined 0.9% year over year, pointing to weak top-line momentum. Net margin of 4.0% is modest, leaving limited room for execution missteps or cost pressure.
What is BVS's revenue and growth?
Bioventus Inc. reported revenue of $132.1M.
Does BVS pay dividends?
Bioventus Inc. does not currently pay dividends.
Where can I find BVS SEC filings?
Official SEC filings for Bioventus Inc. (CIK: 0001665988) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BVS's EPS?
Bioventus Inc. has a diluted EPS of $0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BVS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Bioventus Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BVS stock overvalued or undervalued?
Valuation metrics for BVS: ROE of 1.6% (sector avg: 15%), net margin of 2.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BVS stock in 2026?
Our dual AI analysis gives Bioventus Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BVS's free cash flow?
Bioventus Inc.'s operating cash flow is $8.9M, with capital expenditures of $574.0K. FCF margin is 6.3%.
How does BVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.4% (avg: 12%), ROE 1.6% (avg: 15%), current ratio 1.69 (avg: 2).